Internal Medicine, Hematology & Oncology · Bridgewater, NJ
NPI
1881910263
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1200 US Highway 22 Ste 3
Bridgewater, NJ, 08807
Phone (732) 390-7750
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.0M
76,634 services
Medicare patients, 2024
497
Average age 75
Drug cost, 2024
$2.8M
1,036 prescriptions
Company payments, 2025
$353
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Beiqing Pan was code J1439 (injection, ferric carboxymaltose, 1 mg), 24,000 times for 23 patients. In total Beiqing Pan billed 76,634 services in 114 codes, and Medicare paid $1.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 24,000 | 23 | $0.88 | $21K |
| J0897 Injection, denosumab, 1 mg | Office | 1,320 | 11 | $20.25 | $27K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 592 | 19 | $0.09 | $53.77 |
| 99232 Hospital E&M - Subsequent | Facility | 501 | 126 | $71.71 | $36K |
| 99214 Office E&M - Established | Office | 421 | 200 | $110.32 | $46K |
| 85025 Blood Count | Office | 381 | 150 | $7.61 | $2,899 |
| 36415 Venipuncture Blood Collection | Office | 370 | 155 | $8.65 | $3,201 |
| 96372 Injection Administration | Office | 230 | 67 | $13.06 | $3,004 |
| 85027 Blood Count | Office | 193 | 79 | $6.34 | $1,224 |
| 96367 Intravenous Infusion, Hydration | Office | 157 | 34 | $27.22 | $4,274 |
| 96413 Chemotherapy Administration | Office | 135 | 41 | $123.77 | $17K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 128 | 58 | $14.75 | $1,888 |
| 85610 Clinical Chemistry | Office | 80 | 11 | $4.20 | $336 |
| 99222 Hospital E&M - Initial | Facility | 79 | 70 | $119.19 | $9,416 |
| 96365 Intravenous Infusion, Hydration | Office | 66 | 43 | $56.49 | $3,728 |
By year: 2022 $970K for 61,541 services; 2023 $1.4M for 102,391 services; 2024 $1.0M for 76,634 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 381 | 150 | $7.61 | $2,899 |
| 36415 Venipuncture Blood Collection | 370 | 155 | $8.65 | $3,201 |
| 85027 Blood Count | 193 | 79 | $6.34 | $1,224 |
| 85610 Clinical Chemistry | 80 | 11 | $4.20 | $336 |
Medicare prescription drug claims, 2024
In 2024, the drug Beiqing Pan prescribed most often to Medicare patients was Anastrozole, with 125 prescriptions and refills. In total Beiqing Pan wrote 1,036 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 125 | 308 | 39 | $2,107 |
| Eliquis Apixaban | 111 | 182 | 27 | $98K |
| Aranesp Darbepoetin Alfa In Polysorbat | 79 | 79 | 12 | $95K |
| Warfarin Sodium Generic | 72 | 183 | 13 | $668 |
| Oxycodone Hcl Generic | 30 | 30 | Under 11 | $621 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 26 | 26 | Under 11 | $392 |
| Hydroxyurea Generic | 24 | 54 | Under 11 | $306 |
| Procrit Epoetin Alfa | 24 | 24 | Under 11 | $46K |
| Oxycontin Oxycodone Hcl | 20 | 20 | Under 11 | $31K |
| Tagrisso Osimertinib Mesylate | 19 | 19 | Under 11 | $310K |
| Lupron Depot Leuprolide Acetate | 18 | 54 | Under 11 | $99K |
| Kisqali Ribociclib Succinate | 18 | 18 | Under 11 | $294K |
| Prednisone Generic | 17 | 17 | Under 11 | $53.41 |
| Lenalidomide Generic | 16 | 16 | Under 11 | $202K |
| Dexamethasone Generic | 16 | 18 | Under 11 | $281 |
Brand drugs: - claims; generic drugs: 568 claims; opioid claims: 96.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Beiqing Pan $353 ($353 in general payments such as food, travel and fees) from 10 companies. The largest payer was Daiichi Sankyo Inc. with $152.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 8 | $152 |
| Exelixis Inc. EXEL | 2 | $37.27 |
| Abbvie Inc. ABBV | 2 | $37.02 |
| GlaxoSmithKline, LLC. GSK | 2 | $32.73 |
| Pharmacosmos Therapeutics Inc. | 1 | $20.96 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $19.57 |
| Gilead Sciences, Inc. GILD | 1 | $18.02 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $18 |
| Puma Biotechnology, Inc. PBYI | 1 | $17.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.